CN102036996A - 作为hiv整合酶抑制剂的桥接杂环 - Google Patents
作为hiv整合酶抑制剂的桥接杂环 Download PDFInfo
- Publication number
- CN102036996A CN102036996A CN2009801183261A CN200980118326A CN102036996A CN 102036996 A CN102036996 A CN 102036996A CN 2009801183261 A CN2009801183261 A CN 2009801183261A CN 200980118326 A CN200980118326 A CN 200980118326A CN 102036996 A CN102036996 A CN 102036996A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- hydrogen
- methyl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *S(N(CCN1C(I)=O)C1=O)(=O)=O Chemical compound *S(N(CCN1C(I)=O)C1=O)(=O)=O 0.000 description 26
- VETOCVNDVZIMIW-UHFFFAOYSA-N CC(C)(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C)c1F)=O)=C2O)=O)[n]1nnc(C(O)=O)c1 Chemical compound CC(C)(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(C)c1F)=O)=C2O)=O)[n]1nnc(C(O)=O)c1 VETOCVNDVZIMIW-UHFFFAOYSA-N 0.000 description 1
- OVOULGBWOROMII-OVCLIPMQSA-N CC(C)(CN1c2c(/C=N/C)ccc(F)c2)N(C)S1(=O)=O Chemical compound CC(C)(CN1c2c(/C=N/C)ccc(F)c2)N(C)S1(=O)=O OVOULGBWOROMII-OVCLIPMQSA-N 0.000 description 1
- ITAGEFAMGIFUAA-UHFFFAOYSA-N CC(CC1)(CCC1(C1=NC(C(NCc(cc2)ccc2F)=O)=C2O)NC(OCc3ccccc3)=O)CN1C2=O Chemical compound CC(CC1)(CCC1(C1=NC(C(NCc(cc2)ccc2F)=O)=C2O)NC(OCc3ccccc3)=O)CN1C2=O ITAGEFAMGIFUAA-UHFFFAOYSA-N 0.000 description 1
- AJMVIUIAPDDREJ-UHFFFAOYSA-N CC(N(CC1)CCN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O)=O Chemical compound CC(N(CC1)CCN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O)=O AJMVIUIAPDDREJ-UHFFFAOYSA-N 0.000 description 1
- WHCYSXVNBUOBMC-UHFFFAOYSA-N CC(Nc1cncc(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)c1)=O Chemical compound CC(Nc1cncc(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)c1)=O WHCYSXVNBUOBMC-UHFFFAOYSA-N 0.000 description 1
- RFOMYNSMIDTLLS-UHFFFAOYSA-N CCC(CCC(C)CN1C2=O)(C1=NC(C(NCc(cc1)c(CO)cc1F)=O)=C2O)NC(C(N(C)C)=O)=O Chemical compound CCC(CCC(C)CN1C2=O)(C1=NC(C(NCc(cc1)c(CO)cc1F)=O)=C2O)NC(C(N(C)C)=O)=O RFOMYNSMIDTLLS-UHFFFAOYSA-N 0.000 description 1
- DPAXPTSVZJAGMY-UHFFFAOYSA-N CCN(CC)C(C(NC(CC1)(CC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CCN(CC)C(C(NC(CC1)(CC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O DPAXPTSVZJAGMY-UHFFFAOYSA-N 0.000 description 1
- XDKTXTKZOLVOPZ-UHFFFAOYSA-N CCN(Cc1ccccc1)C(CC1)(CCC1CN1C2=O)C1=NC(C(OCC)=O)=C2OC(c1ccccc1)=O Chemical compound CCN(Cc1ccccc1)C(CC1)(CCC1CN1C2=O)C1=NC(C(OCC)=O)=C2OC(c1ccccc1)=O XDKTXTKZOLVOPZ-UHFFFAOYSA-N 0.000 description 1
- RNYCKGSYBGEKLF-UHFFFAOYSA-N CCOC(C(N=C(C(C(CC1)CC1C1)N(C)C(OCc2ccccc2)=O)N1C1=O)=C1OC(c1ccccc1)=O)=O Chemical compound CCOC(C(N=C(C(C(CC1)CC1C1)N(C)C(OCc2ccccc2)=O)N1C1=O)=C1OC(c1ccccc1)=O)=O RNYCKGSYBGEKLF-UHFFFAOYSA-N 0.000 description 1
- WZJVXAWKNXDSEA-UHFFFAOYSA-N CCOC(C(N=C(C(C)(CCC(C)C1)OC)N1C1=O)=C1O)=O Chemical compound CCOC(C(N=C(C(C)(CCC(C)C1)OC)N1C1=O)=C1O)=O WZJVXAWKNXDSEA-UHFFFAOYSA-N 0.000 description 1
- DUKXHNULXFLBHW-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CCC1C1)N(C)Cc2ccccc2)N1C1=O)=C1OC(c1ccccc1)=O)=O Chemical compound CCOC(C(N=C(C(CC1)(CCC1C1)N(C)Cc2ccccc2)N1C1=O)=C1OC(c1ccccc1)=O)=O DUKXHNULXFLBHW-UHFFFAOYSA-N 0.000 description 1
- KZEWADHVGOGKCO-UHFFFAOYSA-N CCOC(C(N=C(C(CC1)(CCC1C1)NC)N1C1=O)=C1OC(c1ccccc1)=O)=O Chemical compound CCOC(C(N=C(C(CC1)(CCC1C1)NC)N1C1=O)=C1OC(c1ccccc1)=O)=O KZEWADHVGOGKCO-UHFFFAOYSA-N 0.000 description 1
- GCBDWQRRSXORIF-UHFFFAOYSA-N CCOC(C(N=C(C(CCC1)(CC1C1)OCC(N(C)C)=O)N1C1=O)=C1OCc1ccccc1)=O Chemical compound CCOC(C(N=C(C(CCC1)(CC1C1)OCC(N(C)C)=O)N1C1=O)=C1OCc1ccccc1)=O GCBDWQRRSXORIF-UHFFFAOYSA-N 0.000 description 1
- SULKRSZDDAMGCT-UHFFFAOYSA-N CN(C)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O SULKRSZDDAMGCT-UHFFFAOYSA-N 0.000 description 1
- FWQMQEPBTRUHJT-UHFFFAOYSA-N CN(C)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(OC)=O)=C2O)=O)=O Chemical compound CN(C)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(OC)=O)=C2O)=O)=O FWQMQEPBTRUHJT-UHFFFAOYSA-N 0.000 description 1
- ZQLLHUYEVKIIHD-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(OC)c1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)cc(OC)c1F)=O)=C2O)=O)=O ZQLLHUYEVKIIHD-UHFFFAOYSA-N 0.000 description 1
- SMZOGFLGAPGMAP-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(ccc(F)c1)c1Cl)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(ccc(F)c1)c1Cl)=O)=C2O)=O)=O SMZOGFLGAPGMAP-UHFFFAOYSA-N 0.000 description 1
- OZTNYZPSQUMTAM-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc1ccccc1)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc1ccccc1)=O)=C2O)=O)=O OZTNYZPSQUMTAM-UHFFFAOYSA-N 0.000 description 1
- BJEWBFDRFTVFKG-UHFFFAOYSA-N CN(C)C(C(NC(CC1)(COC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CC1)(COC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O BJEWBFDRFTVFKG-UHFFFAOYSA-N 0.000 description 1
- UMEMPSHJOOZDNP-UHFFFAOYSA-N CN(C)C(C(NC(CCC1)(CC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)C(C(NC(CCC1)(CC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O UMEMPSHJOOZDNP-UHFFFAOYSA-N 0.000 description 1
- FOTAJOSSUSRAFX-UHFFFAOYSA-N CN(C)CCN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(C)CCN(C)C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O FOTAJOSSUSRAFX-UHFFFAOYSA-N 0.000 description 1
- GCIJFYBEWXERMA-UHFFFAOYSA-N CN(CCF)C(C(NC(CC1)(CC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=N Chemical compound CN(CCF)C(C(NC(CC1)(CC1CCN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=N GCIJFYBEWXERMA-UHFFFAOYSA-N 0.000 description 1
- AWDJHWKLUFEZJB-UHFFFAOYSA-N CN(CCOC)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound CN(CCOC)C(C(N(C)C(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O AWDJHWKLUFEZJB-UHFFFAOYSA-N 0.000 description 1
- SEPUAJNTZXSBDG-UHFFFAOYSA-N CNC(C(CC1)CC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O Chemical compound CNC(C(CC1)CC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O SEPUAJNTZXSBDG-UHFFFAOYSA-N 0.000 description 1
- YBLAKNHKBYYFPK-UHFFFAOYSA-N CNC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O Chemical compound CNC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O YBLAKNHKBYYFPK-UHFFFAOYSA-N 0.000 description 1
- UVOWTUHCRSTBDI-UHFFFAOYSA-N CS(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)(=O)=O Chemical compound CS(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)(=O)=O UVOWTUHCRSTBDI-UHFFFAOYSA-N 0.000 description 1
- LNPOPQCFZADSGM-UHFFFAOYSA-N CS(c(cc1)ccc1SN1CCOCC1)(=O)=O Chemical compound CS(c(cc1)ccc1SN1CCOCC1)(=O)=O LNPOPQCFZADSGM-UHFFFAOYSA-N 0.000 description 1
- QUCYSYSKATXQHV-OFYDKUIBSA-N C[C@H](C1)O[C@@H](C)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O Chemical compound C[C@H](C1)O[C@@H](C)CN1C(C(NC(CC1)(CCC1CN1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O)=O)=O QUCYSYSKATXQHV-OFYDKUIBSA-N 0.000 description 1
- ZFLXYQBTRUJCEI-UHFFFAOYSA-N C[n]1cnc(S(N(CC2)CCN2C(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)=O)(=O)=O)c1 Chemical compound C[n]1cnc(S(N(CC2)CCN2C(C(NC(CC2)(CCC2CN2C3=O)C2=NC(C(NCc(cc2)ccc2F)=O)=C3O)=O)=O)(=O)=O)c1 ZFLXYQBTRUJCEI-UHFFFAOYSA-N 0.000 description 1
- BPFKRYLQPMNFKY-UHFFFAOYSA-N Cc(c(Br)c(CN)c(Br)c1)c1F Chemical compound Cc(c(Br)c(CN)c(Br)c1)c1F BPFKRYLQPMNFKY-UHFFFAOYSA-N 0.000 description 1
- QNESWIAEQAPLGW-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CC1CC1)NC(C(N(C)C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CC1CC1)NC(C(N(C)C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F QNESWIAEQAPLGW-UHFFFAOYSA-N 0.000 description 1
- OSKFVQDDQXYSDJ-QSBSHVOESA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(C(N(CC2)C[C@@H]2F)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(C(N(CC2)C[C@@H]2F)=O)=O)N1C1=O)=C1O)=O)cc1)c1F OSKFVQDDQXYSDJ-QSBSHVOESA-N 0.000 description 1
- VUKWHWLWVFZJHN-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(c2cnccc2)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)N(C)C(c2cnccc2)=O)N1C1=O)=C1O)=O)cc1)c1F VUKWHWLWVFZJHN-UHFFFAOYSA-N 0.000 description 1
- BVTHWTNHQIWKRK-QOVAFXAKSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(C[C@@H](C2)OC)N2C(c2ccc[n]2C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(C(C[C@@H](C2)OC)N2C(c2ccc[n]2C)=O)=O)N1C1=O)=C1O)=O)cc1)c1F BVTHWTNHQIWKRK-QOVAFXAKSA-N 0.000 description 1
- DGSQGYVKEVAQCR-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(NC)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(NC)=O)N1C1=O)=C1O)=O)cc1)c1F DGSQGYVKEVAQCR-UHFFFAOYSA-N 0.000 description 1
- NJAUEMQUEHQKAS-UHFFFAOYSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(Nc2ccccn2)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC(Nc2ccccn2)=O)N1C1=O)=C1O)=O)cc1)c1F NJAUEMQUEHQKAS-UHFFFAOYSA-N 0.000 description 1
- PAHPNYQOLWVMFQ-CLEJVJKTSA-N Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC([C@H](CC(C2)(F)F)N2S(C)(=O)=O)=O)N1C1=O)=C1O)=O)cc1)c1F Chemical compound Cc(cc(CNC(C(N=C(C(CC1)(CCC1C1)NC([C@H](CC(C2)(F)F)N2S(C)(=O)=O)=O)N1C1=O)=C1O)=O)cc1)c1F PAHPNYQOLWVMFQ-CLEJVJKTSA-N 0.000 description 1
- WBSVWCVEOCMXKT-UHFFFAOYSA-N ICC(CC1)CCN1I Chemical compound ICC(CC1)CCN1I WBSVWCVEOCMXKT-UHFFFAOYSA-N 0.000 description 1
- JKMNYGUBPHJNNU-UHFFFAOYSA-N NC(CC1)(CCC1N1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O Chemical compound NC(CC1)(CCC1N1C2=O)C1=NC(C(NCc(cc1)ccc1F)=O)=C2O JKMNYGUBPHJNNU-UHFFFAOYSA-N 0.000 description 1
- OAQAIZNHFZDAGY-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CC2C2)NC(OCc3ccccc3)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CC2C2)NC(OCc3ccccc3)=O)N2C1=O OAQAIZNHFZDAGY-UHFFFAOYSA-N 0.000 description 1
- QIRGXKCXADCFFK-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3C(c3ccc[s]3)=O)=O)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3C(c3ccc[s]3)=O)=O)=O)N2C1=O QIRGXKCXADCFFK-UHFFFAOYSA-N 0.000 description 1
- WFDDAFLDFZRGID-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3S(c(cc3)ccc3S(N3CCOCC3)(=O)=O)(=O)=O)=O)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3S(c(cc3)ccc3S(N3CCOCC3)(=O)=O)(=O)=O)=O)=O)N2C1=O WFDDAFLDFZRGID-UHFFFAOYSA-N 0.000 description 1
- RWDDXIGJBNNOIJ-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3c3ccccn3)=O)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(C(N(CC3)CCN3c3ccccn3)=O)=O)N2C1=O RWDDXIGJBNNOIJ-UHFFFAOYSA-N 0.000 description 1
- VJNZKLJSFUPHBL-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3cccnc3)=O)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C(CC2)(CCC2C2)NC(c3cccnc3)=O)N2C1=O VJNZKLJSFUPHBL-UHFFFAOYSA-N 0.000 description 1
- AIYJIRVPBWXJDZ-UHFFFAOYSA-N OC1=C(C(NCc2ccccc2)=O)N=C(N(CC2)CCC2C2)N2C1=O Chemical compound OC1=C(C(NCc2ccccc2)=O)N=C(N(CC2)CCC2C2)N2C1=O AIYJIRVPBWXJDZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3772908P | 2008-03-19 | 2008-03-19 | |
| US61/037,729 | 2008-03-19 | ||
| US12/406,268 US8129398B2 (en) | 2008-03-19 | 2009-03-18 | HIV integrase inhibitors |
| US12/406,268 | 2009-03-18 | ||
| PCT/US2009/037596 WO2009117540A1 (en) | 2008-03-19 | 2009-03-19 | Bridged heterocycles as hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102036996A true CN102036996A (zh) | 2011-04-27 |
Family
ID=40863725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801183261A Pending CN102036996A (zh) | 2008-03-19 | 2009-03-19 | 作为hiv整合酶抑制剂的桥接杂环 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8129398B2 (https=) |
| EP (1) | EP2280981B8 (https=) |
| JP (1) | JP2011515412A (https=) |
| KR (1) | KR20100137522A (https=) |
| CN (1) | CN102036996A (https=) |
| AU (1) | AU2009225577A1 (https=) |
| BR (1) | BRPI0910307A2 (https=) |
| CA (1) | CA2718950A1 (https=) |
| CO (1) | CO6331439A2 (https=) |
| EA (1) | EA201001508A1 (https=) |
| IL (1) | IL208068A0 (https=) |
| MX (1) | MX2010009995A (https=) |
| NZ (1) | NZ588031A (https=) |
| WO (1) | WO2009117540A1 (https=) |
| ZA (1) | ZA201006589B (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| CN103601613A (zh) * | 2013-11-19 | 2014-02-26 | 上虞市临江化工有限公司 | 一种3,4,5-三氟溴苯的制备方法 |
| CN104583214A (zh) * | 2012-08-16 | 2015-04-29 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制的抑制剂 |
| CN105008369A (zh) * | 2013-03-14 | 2015-10-28 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2391212A4 (en) * | 2009-01-28 | 2012-08-08 | BROKEN COMPOUNDS AS HIV INTEGRASE INHIBITORS | |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
| CA2807546C (en) | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US8846659B2 (en) | 2010-12-10 | 2014-09-30 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2012077221A1 (ja) * | 2010-12-10 | 2012-06-14 | アグロカネショウ株式会社 | ３-アミノオキサリルアミノベンズアミド誘導体及びこれを有効成分とする殺虫、殺ダニ剤 |
| US8835411B2 (en) * | 2010-12-10 | 2014-09-16 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CN102675305B (zh) * | 2011-03-08 | 2014-11-12 | 中国科学院上海药物研究所 | 一类咪唑并吡啶类化合物及其制备方法和用途 |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| KR20150103269A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| MX2015008627A (es) | 2013-01-04 | 2015-09-23 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| SI3019503T1 (sl) | 2013-07-12 | 2017-11-30 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij |
| NO2865735T3 (https=) | 2013-07-12 | 2018-07-21 | ||
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| EP3139930B1 (en) | 2014-05-05 | 2024-08-14 | Melinta Therapeutics, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| ES2750805T3 (es) | 2014-05-05 | 2020-03-27 | Rempex Pharmaceuticals Inc | Síntesis de sales de boronato y usos de las mismas |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| NO2717902T3 (https=) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2016003929A1 (en) | 2014-07-01 | 2016-01-07 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| JP6402259B2 (ja) | 2015-04-02 | 2018-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | 多環式カルバモイルピリドン化合物およびそれらの薬学的使用 |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017059120A1 (en) * | 2015-09-30 | 2017-04-06 | Gilead Sciences, Inc. | Compounds and combinations for the treatment of hiv |
| MX389349B (es) | 2016-06-30 | 2025-03-20 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos. |
| US11286270B2 (en) | 2017-10-11 | 2022-03-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis thereof |
| EP3781576B1 (en) | 2018-04-20 | 2024-06-12 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| WO2020197991A1 (en) * | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| IL295677B1 (en) | 2020-02-24 | 2026-04-01 | Gilead Sciences Inc | Tetracyclic compounds for the treatment of HIV infection |
| AU2021266715A1 (en) | 2020-05-05 | 2022-11-17 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof |
| CA3192145A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| FI4196479T3 (fi) | 2021-01-19 | 2024-01-17 | Gilead Sciences Inc | Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1578748B1 (en) * | 2002-12-27 | 2010-09-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7173022B2 (en) * | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) * | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) * | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) * | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| CN101146811B (zh) | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| CA2607151C (en) | 2005-05-10 | 2012-06-19 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| US7897592B2 (en) * | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) * | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7897593B2 (en) * | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| EP2391212A4 (en) * | 2009-01-28 | 2012-08-08 | BROKEN COMPOUNDS AS HIV INTEGRASE INHIBITORS |
-
2009
- 2009-03-18 US US12/406,268 patent/US8129398B2/en active Active
- 2009-03-19 EP EP09722517.1A patent/EP2280981B8/en not_active Not-in-force
- 2009-03-19 JP JP2011500942A patent/JP2011515412A/ja active Pending
- 2009-03-19 NZ NZ588031A patent/NZ588031A/en not_active IP Right Cessation
- 2009-03-19 MX MX2010009995A patent/MX2010009995A/es not_active Application Discontinuation
- 2009-03-19 BR BRPI0910307A patent/BRPI0910307A2/pt not_active IP Right Cessation
- 2009-03-19 KR KR1020107023261A patent/KR20100137522A/ko not_active Withdrawn
- 2009-03-19 WO PCT/US2009/037596 patent/WO2009117540A1/en not_active Ceased
- 2009-03-19 CN CN2009801183261A patent/CN102036996A/zh active Pending
- 2009-03-19 EA EA201001508A patent/EA201001508A1/ru unknown
- 2009-03-19 AU AU2009225577A patent/AU2009225577A1/en not_active Abandoned
- 2009-03-19 CA CA2718950A patent/CA2718950A1/en not_active Abandoned
-
2010
- 2010-09-07 IL IL208068A patent/IL208068A0/en unknown
- 2010-09-14 ZA ZA2010/06589A patent/ZA201006589B/en unknown
- 2010-09-16 CO CO10115016A patent/CO6331439A2/es not_active Application Discontinuation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| CN104583214A (zh) * | 2012-08-16 | 2015-04-29 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制的抑制剂 |
| CN104583214B (zh) * | 2012-08-16 | 2017-06-09 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制的抑制剂 |
| CN105008369A (zh) * | 2013-03-14 | 2015-10-28 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
| CN105008369B (zh) * | 2013-03-14 | 2017-07-11 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
| CN103601613A (zh) * | 2013-11-19 | 2014-02-26 | 上虞市临江化工有限公司 | 一种3,4,5-三氟溴苯的制备方法 |
| CN103601613B (zh) * | 2013-11-19 | 2015-07-08 | 浙江林江化工股份有限公司 | 一种3,4,5-三氟溴苯的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2280981B1 (en) | 2014-04-23 |
| EA201001508A1 (ru) | 2011-04-29 |
| MX2010009995A (es) | 2010-09-30 |
| EP2280981A1 (en) | 2011-02-09 |
| ZA201006589B (en) | 2012-02-29 |
| CO6331439A2 (es) | 2011-10-20 |
| NZ588031A (en) | 2011-12-22 |
| US20090253677A1 (en) | 2009-10-08 |
| AU2009225577A1 (en) | 2009-09-24 |
| KR20100137522A (ko) | 2010-12-30 |
| IL208068A0 (en) | 2010-12-30 |
| WO2009117540A1 (en) | 2009-09-24 |
| JP2011515412A (ja) | 2011-05-19 |
| CA2718950A1 (en) | 2009-09-24 |
| BRPI0910307A2 (pt) | 2019-09-24 |
| US8129398B2 (en) | 2012-03-06 |
| EP2280981B8 (en) | 2014-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102036996A (zh) | 作为hiv整合酶抑制剂的桥接杂环 | |
| CN109641896B (zh) | 二氮杂酮衍生物及其在治疗乙型肝炎感染中的用途 | |
| TWI685493B (zh) | 抑制mcl-1蛋白之化合物 | |
| CN109843892B (zh) | 噁二氮杂卓酮衍生物及其在治疗乙型肝炎感染中的用途 | |
| TWI519519B (zh) | 作爲ｍｄｍ２抑制劑以治療癌症之六氫吡啶酮衍生物 | |
| CN116670143A (zh) | 囊性纤维化跨膜传导调控因子的调节剂 | |
| CN101821267B (zh) | 用于治疗丙型肝炎的化合物 | |
| EA016614B1 (ru) | Соединения для лечения гепатита с | |
| WO2009067108A1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| TW201615644A (zh) | 作為人類免疫缺乏病毒複製之抑制劑的吡唑并嘧啶巨環化合物 | |
| CN120603836A (zh) | 可用于治疗神经退化疾病的1-氨基-4-苯基酞嗪衍生物 | |
| HK40094055A (zh) | 可用於治疗呼吸道合胞病毒感染的苯二氮杂䓬衍生物 | |
| HK40007197A (en) | Diazepinone derivatives and their use in the treatment of hepatitis b infections | |
| HK40008527A (en) | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections | |
| HK1186462B (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110427 |